Latest Ratios: P/E Ratio -2.7x · EV/EBITDA N/A · ROE -152.1%. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $79M | $254.1B | $80.5B | $256.6B | — | — |
| Enterprise Value | $1.1B | $90M | $254.1B | $80.5B | $256.6B | — | — |
| P/E Ratio → | -2.69 | — | — | — | — | — | — |
| P/S Ratio | 66.56 | 4.85 | 62719.10 | 553832.30 | 502130.45 | — | — |
| P/B Ratio | 8.37 | 7.17 | 48202.20 | — | 38251.14 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 5.51 | 62722.60 | 553860.97 | 502125.80 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 49.1% | 49.1% | 38.7% | 8.9% | 32.7% | 100.0% | 100.0% |
| Operating Margin | -63.1% | -63.1% | -191.6% | -15271.2% | -7860.5% | -12525.8% | -13857.1% |
| Net Profit Margin | -75.9% | -75.9% | -306.2% | -18205.2% | -18640.9% | -32073.3% | -13734.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -152.1% | -152.1% | -235.3% | — | -1420.0% | — | -99.2% |
| ROA | -28.8% | -28.8% | -58.5% | -146.4% | -289.9% | -193.8% | -91.8% |
| ROIC | -37.5% | -37.5% | -122.3% | — | -1351.2% | -3114.2% | — |
| ROCE | -83.0% | -83.0% | -86.4% | -298.1% | -353.3% | -984.7% | -99.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.99 | 0.99 | 2.70 | — | 0.47 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.97 | 2.69 | — | -0.35 | — | -0.93 |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -2.68 | -2.68 | -2.18 | -23.87 | -65.15 | -33.43 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.11 | 0.11 | 0.09 | 0.02 | 1.78 | 0.21 | 14.00 |
| Quick Ratio | 0.10 | 0.10 | 0.08 | 0.02 | 1.59 | 0.20 | 14.00 |
| Cash Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.80 | 0.19 | 13.23 |
| Asset Turnover | — | 0.37 | 0.10 | 0.20 | 0.01 | 0.00 | 0.01 |
| Inventory Turnover | 45.36 | 45.36 | 15.39 | — | 0.26 | — | — |
| Days Sales Outstanding | — | 55.04 | 204.59 | 251.22 | 71.43 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $265M | $15M | $4M | $1M | $582000 | $200000 |
Imminent liquidity crisis
According to current market data, FOXO trades at a P/S multiple of 0.02, a figure that, when compared to broader healthcare information services peers, suggests the market is pricing in extreme execution risk and the potential for significant future shareholder dilution to fund ongoing operations.
The lack of meaningful P/E or EV/EBITDA multiples underscores the company's inability to generate positive earnings or EBITDA, rendering traditional valuation metrics largely irrelevant. Investors should interpret this low P/S ratio not as a bargain, but as a reflection of the market's skepticism regarding the company's ability to convert its epigenetic testing volume into a sustainable, profitable business model.
As reported in recent financial statements, FOXO maintains a gross margin of 51.0% as of 2026Q1, yet this is consistently undermined by an operating margin of -63.11%, indicating that the firm has yet to achieve the scale necessary to cover its substantial fixed bioinformatics and actuarial overhead.
While the gross margin suggests the core testing service has inherent value, the persistent negative operating margin reveals a structural disconnect between revenue generation and the cost of maintaining the firm's specialized infrastructure. This suggests that until the company can transition to a high-volume, automated licensing model, profitability will likely remain elusive regardless of top-line growth.
Based on the provided quarterly data, FOXO's cash conversion cycle remains highly volatile, with a negative CCC of -193 days in 2026Q1, which, while appearing efficient, likely reflects an inability to manage payables effectively rather than a genuine competitive advantage in working capital management.
The extreme fluctuations in the CCC, coupled with high DSO figures, suggest that the company is struggling to collect on its service contracts in a timely manner. This inefficiency forces a reliance on external capital to bridge the gap between service delivery and cash receipt, further exacerbating the firm's liquidity challenges.
As indicated by recent SEC filings, FOXO's current ratio of 0.14 and cash reserves of approximately $207,453 highlight a severe liquidity crisis that leaves the company with virtually no buffer to absorb operational shocks or fund the necessary customer acquisition to drive future growth.
The current liquidity position is critically low, suggesting that the company may be unable to meet its short-term obligations without immediate capital intervention. Investors should monitor for potential going-concern warnings, as the current burn rate appears fundamentally incompatible with the company's existing cash-on-hand.
The most commonly misapplied metric for FOXO is the P/S ratio, which fails to account for the company's high fixed-cost structure and the non-recurring nature of its pilot-driven revenue, thereby obscuring the true extent of the firm's operational fragility and its reliance on external financing.
Analysts should instead focus on the cash-to-burn ratio and the trend in operating cash flow, as these metrics provide a more accurate picture of the company's survival prospects. Relying on revenue multiples in a business model that has yet to prove its path to profitability can lead to a dangerous underestimation of the capital risk inherent in this investment.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FOXO stock.
FOXO Technologies Inc.'s current P/E ratio is -2.7x. This places it at the 50th percentile of its historical range.
FOXO Technologies Inc.'s return on equity (ROE) is -152.1%. The historical average is -162.2%.
Based on historical data, FOXO Technologies Inc. is trading at a P/E of -2.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
FOXO Technologies Inc. has 49.1% gross margin and -63.1% operating margin.